Supernus Pharmaceuticals (SUPN) Aktievy
Supernus Pharmaceuticals, Inc, ett biofarmaceutiskt företag, bedriver utveckling och kommersialisering av produkter för behandling av sjukdomar i centrala nervsystemet (CNS) i USA. Mer information
| Snöflinga Score | |
|---|---|
| Värdering | 6/6 |
| Framtida tillväxt | 3/6 |
| Tidigare resultat | 0/6 |
| Finansiell hälsa | 6/6 |
| Utdelningar | 0/6 |
Belöningar
Riskanalys
Inga risker upptäckta för SUPN från våra riskkontroller.
SUPN Community Fair Values
Create NarrativeSee what 12 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Supernus Pharmaceuticals, Inc. Konkurrenter
Prishistorik och prestanda
| Historiska aktiekurser | |
|---|---|
| Aktuell aktiekurs | US$48.05 |
| 52 veckors högsta | US$59.68 |
| 52 veckors lägsta | US$31.35 |
| Beta | 0.54 |
| 1 månads förändring | 7.37% |
| 3 månaders förändring | -4.93% |
| 1 års förändring | 50.25% |
| 3 års förändring | 62.11% |
| 5 års förändring | 69.13% |
| Förändring sedan börsintroduktionen | 794.79% |
Senaste nyheter och uppdateringar
Uppdatering av berättelse • Jun 24
SUPN: Consistent 2026 Guidance And Margins Will Support Forward Repricing
Analysts have maintained their $62.83 price target on Supernus Pharmaceuticals, citing consistent assumptions for revenue growth, profit margin, discount rate, and future P/E in their latest update. What’s in the News for Supernus Pharmaceuticals Supernus Pharmaceuticals reiterated full year 2026 total revenue guidance in the range of US$840 million to US$870 million, including ONAPGO net sales of US$45 million to US$70 million and Trokendi XR and Oxtellar XR net sales of US$40 million to US$50 million.Uppdatering av berättelse • Jun 09
SUPN: Steady 2026 Guidance And Earnings Outlook Will Support Forward Repricing
Analysts have held their price target for Supernus Pharmaceuticals steady at $62.83. This reflects only fine tuned adjustments to revenue growth, profit margin assumptions, and future P/E that leave their overall valuation view unchanged.Uppdatering av berättelse • May 26
SUPN: Resolved Supply Constraints Will Support Forward Repricing Case
Analysts have raised their price target on Supernus Pharmaceuticals stock to $65 from $60, citing updated models after Q4 results and increased confidence that Onapgo supply constraints are easing as additional production capacity comes online. Analyst Commentary Bullish Takeaways Bullish analysts view the higher US$65 price target as reflecting updated Q4 assumptions and a clearer picture of the company’s earnings power.Uppdatering av berättelse • May 11
SUPN: Easing Supply Constraints Will Support Future Repricing Opportunity
Analysts have inched their price target for Supernus Pharmaceuticals higher to $65, supported by refreshed models that factor in updated fair value estimates, modestly different growth and margin assumptions, and greater confidence that Onapgo supply constraints are easing. Analyst Commentary Bullish Takeaways Bullish analysts view the higher US$65 price target as reflecting updated fair value work, where refreshed assumptions on growth and margins support a stronger long-term earnings profile.Recent updates
Uppdatering av berättelse • Jun 24
SUPN: Consistent 2026 Guidance And Margins Will Support Forward Repricing
Analysts have maintained their $62.83 price target on Supernus Pharmaceuticals, citing consistent assumptions for revenue growth, profit margin, discount rate, and future P/E in their latest update. What’s in the News for Supernus Pharmaceuticals Supernus Pharmaceuticals reiterated full year 2026 total revenue guidance in the range of US$840 million to US$870 million, including ONAPGO net sales of US$45 million to US$70 million and Trokendi XR and Oxtellar XR net sales of US$40 million to US$50 million.Uppdatering av berättelse • Jun 09
SUPN: Steady 2026 Guidance And Earnings Outlook Will Support Forward Repricing
Analysts have held their price target for Supernus Pharmaceuticals steady at $62.83. This reflects only fine tuned adjustments to revenue growth, profit margin assumptions, and future P/E that leave their overall valuation view unchanged.Uppdatering av berättelse • May 26
SUPN: Resolved Supply Constraints Will Support Forward Repricing Case
Analysts have raised their price target on Supernus Pharmaceuticals stock to $65 from $60, citing updated models after Q4 results and increased confidence that Onapgo supply constraints are easing as additional production capacity comes online. Analyst Commentary Bullish Takeaways Bullish analysts view the higher US$65 price target as reflecting updated Q4 assumptions and a clearer picture of the company’s earnings power.Uppdatering av berättelse • May 11
SUPN: Easing Supply Constraints Will Support Future Repricing Opportunity
Analysts have inched their price target for Supernus Pharmaceuticals higher to $65, supported by refreshed models that factor in updated fair value estimates, modestly different growth and margin assumptions, and greater confidence that Onapgo supply constraints are easing. Analyst Commentary Bullish Takeaways Bullish analysts view the higher US$65 price target as reflecting updated fair value work, where refreshed assumptions on growth and margins support a stronger long-term earnings profile.Uppdatering av berättelse • Apr 22
SUPN: Resolved Supply Constraints Will Support Future Repricing Potential
Analysts have lifted their price target on Supernus Pharmaceuticals by $5 to $65, citing refreshed models after Q4 results and improved visibility on Onapgo supply as production ramps up with the current supplier and a second source expected in 2027. Analyst Commentary Bullish Takeaways Bullish analysts view the $65 price target, up from $60, as reflecting refreshed forecasts after the latest Q4 update.Uppdatering av berättelse • Apr 07
SUPN: Resolved Supply Constraints And Dual Sourcing Plans Will Support Future Repricing
Narrative Update: Supernus Pharmaceuticals Analyst Price Target Shift Analysts have lifted their price target on Supernus Pharmaceuticals to $65 from $60, citing updated models after Q4 results and expectations that Onapgo supply constraints are now addressed with increased production capacity and a planned second supplier in 2027. Analyst Commentary Analysts see the updated price target as a reflection of fresh Q4 inputs and improved visibility on Onapgo supply.Uppdatering av berättelse • Mar 24
SUPN: Resolved Supply Constraints Will Support Repricing Through Improved Execution
Analysts have lifted their price target on Supernus Pharmaceuticals to $65 from $60, citing updated models after Q4 results and expectations that Onapgo supply constraints are easing with increased production capacity and an additional supplier planned for 2027. Analyst Commentary Bullish Takeaways Bullish analysts see the higher US$65 price target as a reflection of updated models that better align with recent Q4 information and current expectations for the business.Uppdatering av berättelse • Mar 10
SUPN: Supply Resolution And Refined P/E Assumptions Will Support Repricing
Analysts have increased their price target on Supernus Pharmaceuticals to $65 from $60, citing updated models following Q4 results and expectations that Onapgo supply constraints are now resolved with expanded production capacity. Analyst Commentary Bullish Takeaways Bullish analysts see the higher US$65 price target as a reflection of updated Q4 assumptions that support their view of improved execution and earnings potential.Uppdatering av berättelse • Feb 23
SUPN: Stable Fair Value And Refined P/E Assumptions Will Support Repricing
Analysts modestly adjusted their $61.33 price target on Supernus Pharmaceuticals as they updated their assumptions around revenue growth, profit margin, and future P/E. This reflects a more finely tuned view of the company’s earnings power and valuation risk.Uppdatering av berättelse • Feb 09
SUPN: Steady Fair Value And P/E Outlook Will Support Bullish Repricing
Analysts have kept their price target for Supernus Pharmaceuticals broadly steady, citing only modest tweaks to underlying assumptions such as a slightly higher discount rate, minor adjustments to expected revenue growth and profit margin, and a largely unchanged future P/E outlook. Valuation Changes Fair Value Estimate remains unchanged at 61.33.Seeking Alpha • Feb 01
Supernus: Outlook For 2026 Positive, Upholding Buy Rating
Summary Supernus remains a Buy, with shares up >50% since mid-2025 and ~25% upside projected for 2026. Qelbree drives growth, with 2026 net sales expected to exceed $450m; patent expirations are being offset by pipeline and acquisitions. The Sage Therapeutics acquisition adds near-term revenue and pipeline depth, though pipeline maturity limits major new launches before 2027. Estimated forward price-to-sales is <4x; cost synergies and incremental pipeline progress support a bullish long-term multi-billion CNS franchise thesis. Read the full article on Seeking AlphaUppdatering av berättelse • Jan 25
SUPN: Higher 2025 Revenue Guidance Will Support Expanded Future Earnings Multiple
Analysts have adjusted their price target on Supernus Pharmaceuticals to US$61.33 per share, reflecting updated assumptions around discount rate, revenue growth, profit margin, and future P/E that remain broadly in line with prior estimates. What's in the News Supernus Pharmaceuticals raised its 2025 total revenue guidance to a range of US$685 million to US$705 million, including approximately US$75 million to US$85 million from Trokendi XR and Oxtellar XR (Key Developments).Uppdatering av berättelse • Jan 10
SUPN: Higher 2025 Revenue Guidance Will Support Expanded Future Earnings Multiple
Analysts have inched their price target on Supernus Pharmaceuticals higher by about $0.83, citing updated assumptions that include a modest adjustment to fair value, slightly different revenue growth and profit margin expectations, and a higher future P/E multiple. What's in the News Supernus Pharmaceuticals raised its 2025 total revenue guidance to a range of US$685 million to US$705 million, including approximately US$75 million to US$85 million from Trokendi XR and Oxtellar XR (Key Developments).Uppdatering av berättelse • Dec 19
SUPN: Faster Therapy Adoption Will Drive Shares Toward Higher Future Upside
Analysts have raised their price target on Supernus Pharmaceuticals to $65, up from $40, citing a faster than expected ramp for ONAPGO and the potential for additional upside beyond current peak sales assumptions. Analyst Commentary Recent research updates reflect a constructive shift in sentiment toward Supernus, with multiple firms lifting price targets and emphasizing the upside from ONAPGO's adoption curve.Uppdatering av berättelse • Dec 05
SUPN: Upgrades Will Drive Future Upside As Revenue Outlook Tightens
Analysts have raised their price target on Supernus Pharmaceuticals to $65 from $40, reflecting growing confidence in stronger ONAPGO uptake and expanded long term earnings potential. Analyst Commentary Recent Street research reflects a more constructive stance on Supernus, with higher price targets supported by improving ONAPGO assumptions and a clearer long term earnings trajectory.Uppdatering av berättelse • Nov 20
SUPN: Upgrades Will Drive Momentum As Earnings Guidance Increases
Analysts have raised their price target for Supernus Pharmaceuticals from $59.33 to $60.50, citing improved revenue growth expectations and increased peak sales forecasts for ONAPGO. Analyst Commentary Recent Street research reflects growing optimism around Supernus Pharmaceuticals, as analysts adjust their targets and ratings in response to strong expectations for ONAPGO and the company’s broader growth trajectory.Uppdatering av berättelse • Nov 05
SUPN: Upgrades And Revenue Outlook Will Shape Performance Amid Execution Risk
Analysts have raised their price target for Supernus Pharmaceuticals by over $4 to approximately $59.33 per share. This change is due to higher future revenue growth expectations and an improved outlook for key therapies.Uppdatering av berättelse • Oct 22
Analysts Boost Price Targets for Supernus Pharmaceuticals on Accelerating Growth and Revenue Outlook
Supernus Pharmaceuticals’ analyst price targets have risen sharply, with the fair value estimate increasing from $49.20 to $55.20 per share as analysts cite accelerating growth prospects and higher peak sales potential in key product lines. Analyst Commentary Bullish Takeaways Bullish analysts have raised their price targets substantially, with figures as high as $65 per share.Uppdatering av berättelse • Oct 08
Widening CNS Access Will Shape Long-term Market Opportunity
Analysts have raised their fair value estimate for Supernus Pharmaceuticals from $40.20 to $49.20, citing a stronger forecast for blockbuster products and higher projected profit margins. This has resulted in a more than $9 increase in their price target.Analysartikel • Sep 10
We Ran A Stock Scan For Earnings Growth And Supernus Pharmaceuticals (NASDAQ:SUPN) Passed With Ease
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...Analysartikel • Jul 23
Benign Growth For Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Underpins Its Share Price
Supernus Pharmaceuticals, Inc.'s ( NASDAQ:SUPN ) price-to-sales (or "P/S") ratio of 3.1x might make it look like a buy...Analysartikel • May 13
Shareholders Can Be Confident That Supernus Pharmaceuticals' (NASDAQ:SUPN) Earnings Are High Quality
Supernus Pharmaceuticals, Inc. ( NASDAQ:SUPN ) just reported healthy earnings but the stock price didn't move much...Analysartikel • Feb 10
Investor Optimism Abounds Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) But Growth Is Lacking
With a price-to-earnings (or "P/E") ratio of 35.5x Supernus Pharmaceuticals, Inc. ( NASDAQ:SUPN ) may be sending very...Seeking Alpha • Feb 06
Supernus: New Approval Holds Promise Of Increased Growth
Summary Supernus Pharmaceuticals' ONAPGO for Parkinson’s Disease received FDA approval, providing a basis for optimism despite past regulatory challenges with SPN-830. The company is methodically planning ONAPGO's market launch in Q2 2025, supported by a robust nurse education program and access support. Continuous subcutaneous apomorphine infusion has a proven 30-year history in Europe, bolstering confidence in ONAPGO's potential success. Supernus' unsteady earnings and unproductive pipeline make it challenging to value, but ONAPGO's approval marks a significant positive development. Read the full article on Seeking AlphaSeeking Alpha • Nov 12
Supernus Pharmaceuticals: Recently Launched Qelbree Is Powering Growth
Summary Supernus Pharmaceuticals recently posted better-than-expected Q3 results, and management also revised FY2024 guidance upward. The ADHD drug Qelbree, which was approved in 2021, is powering revenue growth, and reduced costs are benefiting the bottom line. The company also has a pristine balance sheet with just over $400 million in cash and marketable securities. An updated analysis around Supernus Pharmaceuticals is provided in the paragraphs below. Read the full article on Seeking AlphaAnalysartikel • Oct 31
Supernus Pharmaceuticals, Inc.'s (NASDAQ:SUPN) Share Price Could Signal Some Risk
With a median price-to-sales (or "P/S") ratio of close to 2.9x in the Pharmaceuticals industry in the United States...
Ny berättelse • Sep 12
Qelbree And GOCOVRI Spearhead Robust Revenue Surge, Setting The Path For Market Domination In CNS Therapeutics
Supernus Pharmaceuticals shows robust growth potential with advancements in its product pipeline and significant net sales growth from key products like Qelbree and GOCOVRI.Seeking Alpha • Sep 12
Supernus: Stock Slides As Qelbree Sales Questioned, But Positives Still Outweigh Negatives
Summary Supernus Pharmaceuticals' stock has risen 15% since my last "strong buy" rating, despite recent analyst downgrades due to Qelbree's slowing growth. Supernus' diverse neuroscience portfolio includes key drugs like Qelbree for ADHD and GOCOVRI for Parkinson's, with Qelbree's revenues being potentially seasonally influenced. Despite falling sales of older drugs, Supernus' strong financial position and promising pipeline, including SPN-820 for depression, suggest significant future upside is achievable, but not inevitable. The market may undervalue Supernus, focusing on risks over potential, but strategic M&A and upcoming catalysts like SPN-820 data could drive substantial gains. Read the full article on Seeking AlphaAnalysartikel • Aug 19
Supernus Pharmaceuticals' (NASDAQ:SUPN) Conservative Accounting Might Explain Soft Earnings
The market was pleased with the recent earnings report from Supernus Pharmaceuticals, Inc. ( NASDAQ:SUPN ), despite the...Seeking Alpha • Jul 02
Supernus Pharmaceuticals: So-So Neuroscience Portfolio, With ADHD Standout
Summary Supernus' revenue growth is hindered by rapidly declining Trokendi sales. There are no pipeline products reliably poised to help out with revenues. Qelbree provides the one bright point on Supernus' revenues. Read the full article on Seeking AlphaAnalysartikel • Apr 24
Subdued Growth No Barrier To Supernus Pharmaceuticals, Inc.'s (NASDAQ:SUPN) Price
There wouldn't be many who think Supernus Pharmaceuticals, Inc.'s ( NASDAQ:SUPN ) price-to-sales (or "P/S") ratio of...Seeking Alpha • Mar 04
Supernus Pharmaceuticals: Moving Through An 'Inflection Year'
Summary Today, we take an updated look at Supernus Pharmaceuticals, Inc. after its posted better-than-expected Q4 results last week. The company will be going through an inflection year in 2024 as one core product faces declining sales while two new compounds see considerable sales growth. Supernus used to 2023 to pay off its convertible note obligations and has a debt-free balance sheet with more than $270 million in cash and marketable securities on it. What is ahead for this biopharma company in 2024. An analysis follows in the paragraphs below. Read the full article on Seeking AlphaAnalysartikel • May 10
We Think Supernus Pharmaceuticals (NASDAQ:SUPN) Can Stay On Top Of Its Debt
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Aktieägarnas avkastning
| SUPN | US Pharmaceuticals | US Marknad | |
|---|---|---|---|
| 7D | 2.6% | 1.4% | 1.6% |
| 1Y | 50.3% | 48.6% | 18.6% |
Avkastning vs industri: SUPN översteg US Pharmaceuticals branschen som gav 48.6 % under det senaste året.
Avkastning vs Marknaden: SUPN översteg US marknaden som gav 18.6 % under det senaste året.
Prisvolatilitet
| SUPN volatility | |
|---|---|
| SUPN Average Weekly Movement | 4.2% |
| Pharmaceuticals Industry Average Movement | 9.5% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.2% |
Stabil aktiekurs: SUPN har inte haft någon betydande prisvolatilitet under de senaste 3 månaderna jämfört med marknaden för US.
Volatilitet över tid: SUPN s veckovolatilitet ( 4% ) har varit stabil under det senaste året.
Om företaget
| Grundad | Anställda | VD OCH KONCERNCHEF | Webbplats |
|---|---|---|---|
| 2005 | 778 | Jack Khattar | www.supernus.com |
Supernus Pharmaceuticals, Inc. är ett biofarmaceutiskt företag som bedriver utveckling och kommersialisering av produkter för behandling av sjukdomar i centrala nervsystemet (CNS) i USA. Företaget erbjuder Qelbree, ett icke-stimulerande läkemedel för behandling av ADHD (attention deficit hyperactivity disorder), GOCOVRI för behandling av dyskinesi och levodopa/karbidopa hos patienter med Parkinsons sjukdom (PD), Oxtellar XR, en oxkarbazepinprodukt med förlängd frisättning för monoterapibehandling av partiella epilepsianfall, samt APOKYN för akut och intermittent behandling av hypomobilitet eller off-episoder hos patienter med avancerad PD. Företaget tillhandahåller också Trokendi XR, en topiramatprodukt med förlängd frisättning som är indicerad för behandling av epilepsi samt för profylax av migränhuvudvärk, XADAGO för behandling av levodopa/karbidopa hos patienter med Parkinsons sjukdom som upplever off-episoder samt MYOBLOC, en toxinprodukt av typ B som är indicerad för behandling av cervikal dystoni och kronisk sialorré.
Supernus Pharmaceuticals, Inc. Sammanfattning av grunderna
| SUPN grundläggande statistik | |
|---|---|
| Börsvärde | US$2.79b |
| Vinst(TTM) | -US$29.02m |
| Intäkter(TTM) | US$776.83m |
3.6x
P/S-förhållande-96.1x
P/E-förhållandeÄr SUPN övervärderat?
Se Verkligt värde och värderingsanalysResultat & intäkter
| SUPN resultaträkning (TTM) | |
|---|---|
| Intäkter | US$776.83m |
| Kostnad för intäkter | US$200.94m |
| Bruttovinst | US$575.90m |
| Övriga kostnader | US$604.91m |
| Intäkter | -US$29.02m |
Senast redovisade vinst
Mar 31, 2026
Nästa vinstdatum
n/a
| Vinst per aktie (EPS) | -0.50 |
| Bruttomarginal | 74.13% |
| Nettovinstmarginal | -3.74% |
| Skuld/egenkapitalförhållande | 0% |
Hur har SUPN utvecklats på lång sikt?
Se historisk utveckling och jämförelseFöretagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/07/05 16:27 |
| Aktiekurs vid dagens slut | 2026/07/02 00:00 |
| Intäkter | 2026/03/31 |
| Årlig intjäning | 2025/12/31 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som används för att skapa denna rapport finns på vår Github-sida; vi har också guider om hur du använder våra rapporter och handledningar på Youtube.
Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
Supernus Pharmaceuticals, Inc. bevakas av 17 analytiker. 6 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| Emily Bodnar | Berenberg |
| Chi Meng Fong | BofA Global Research |
| Pavan Patel | BofA Global Research |